FILE- Employees in the EGX following performance of the trading session on December 12, 2017 FILE- Employees in the EGX following performance of the trading session on December 12, 2017

EGX ends Sunday's session in red, market cap. loses LE2B

Sun, Feb. 2, 2020
CAIRO – 2 February 2020: The Egyptian Exchange (EGX) ended Sunday’s session in red, losing LE 2.04 billion of market capitalization, amid Egyptian and Arab selling.

The benchmark EGX 30 dropped 0.22 percent, or 29.95 points, to close at 13,888.89 points.

The equally weighted index EGX 50 dipped 0.76 percent, or 14.67 points, to end at 1,921.21 points.

Moreover, the small and mid-cap index EGX 70 declined 0.64 percent, or 8.12 points, to close at 1,269.36 points, and the broader index EGX 100 decreased 0.66 percent, or 9.26 points to 1,385.85 points.

Market capitalization lost LE 2.04 billion, recording LE 706.10 billion, compared to LE 708.14 billion in Thursday’s session.

The trading volume reached 214.47 million shares, traded through 21,224 transactions, with a turnover of LE 793.91 million.

Foreign investors were net buyers at LE 106.67 million, while Egyptian and Arab investors were net sellers at LE 43.35 million, and LE 63.31 million, respectively.

Egyptian, Arab and foreign individuals were net sellers at LE 35.21 million, LE 22.99 million and LE 390,657, respectively.

Egyptian and Arab organizations sold at LE 8.13 million, and LE 40.32 million, respectively, while foreign organizations bought at LE 107.06 million.

Telecom Egypt, Ismailia National Food Industries, and El Arabia for Land Reclamation were top gainers of the session 12.24 percent, 9.96 percent and 9.92 percent, respectively.

Meanwhile, Ismailia Misr Poultry, Arab Valves Company, and National Housing for Professional Syndicates were top losers of the session by 7.12 percent, 6.62 percent, and 4.89 percent, respectively.

EGX ended Thursday’s session in green, as: EGX 30 hiked 1.13 percent, EGX 50 jumped 1.59 percent, EGX 70 rose 0.76 percent, and EGX 100 increased 0.76 percent.

There are no comments on this article.

Leave a comment